Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ

The estrogen receptor-alpha (ERα) is used as a predictive marker for anti-estrogen therapy in breast cancer patients. In addition to aromatase inhibitors, ERα can be targeted at the receptor level using the receptor modulator tamoxifen or by the pure anti-estrogen fulvestrant. The role of the second...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishra, Ameet K., Abrahamsson, Annelie, Dabrosin, Charlotta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302959/
https://www.ncbi.nlm.nih.gov/pubmed/27486755
http://dx.doi.org/10.18632/oncotarget.10871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302959/
https://www.ncbi.nlm.nih.gov/pubmed/27486755
http://dx.doi.org/10.18632/oncotarget.10871

Ejemplares similares